Wesley Riggs Bagan, MD | |
5409 Avenue O, Fort Madison, IA 52627-9601 | |
(319) 376-2134 | |
(319) 376-2188 |
Full Name | Wesley Riggs Bagan |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 5409 Avenue O, Fort Madison, Iowa |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013919653 | NPI | - | NPPES |
IA0128 | Other | IA | JOHN DEERE HEALTH |
1061614 | Medicaid | IA | |
19555 | Other | IA | WELLMARK BLUE CROSS |
152975 | Other | IA | IOWA HEALTH SOLUTIONS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 27520 (Iowa) | Primary |
Mailing Address | Practice Location Address |
---|---|
Wesley Riggs Bagan, MD 5409 Avenue O, Fort Madison, IA 52627-9601 Ph: (319) 376-2134 | Wesley Riggs Bagan, MD 5409 Avenue O, Fort Madison, IA 52627-9601 Ph: (319) 376-2134 |
News Archive
According to the researchers if current trials are satisfactory, a safe and effective gel which protects women from the AIDS virus may be available by 2010.
Conventional criteria for diagnosing melanoma may not be accurate in children and adolescents, suggest results published in the Journal of the American Academy of Dermatology.
Methane is the world's most abundant hydrocarbon. It's the major component of natural gas and shale gas and, when burned, is an effective fuel. But it's also a major contributor to climate change, with 24 times greater potency as a greenhouse gas than carbon dioxide.
KYTHERA Biopharmaceuticals, Inc. today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness.
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™. This new technology is now available to help physicians objectively assess a patient's pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
› Verified 8 days ago